2 weeks Ago By Defense World Staff
Envestnet Portfolio Solutions Inc. increased its position in Insulet Co. (NASDAQ:PODD – Free Report) by 2.
3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,113 shares of the medical instruments supplier’s stock after buying an additional 48 shares during the quarter. Envestnet Portfolio Solutions Inc.
’s holdings in Insulet were worth $552,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Several other hedge funds and other institutional investors have also bought and sold shares of PODD. Raymond James Financial Inc.
bought a new position in shares of Insulet during the fourth quarter valued at about $69,433,000. Alecta Tjanstepension Omsesidigt bought a new position in Insulet during the 4th quarter worth approximately $53,184,000. Proficio Capital Partners LLC purchased a new position in Insulet in the 4th quarter worth approximately $28,422,000.
Baillie Gifford & Co. lifted its position in Insulet by 3.5% in the fourth quarter.
Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock valued at $614,998,000 after purchasing an additional 79,982 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new stake in shares of Insulet during the third quarter valued at approximately $16,342,000.
Insulet Trading Down 0.5 %Shares of NASDAQ PODD opened at $272.71 on Wednesday.
Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.
46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.
68 and a quick ratio of 2.80. The firm has a 50-day moving average of $272.
27 and a 200 day moving average of $258.19. The stock has a market cap of $19.
15 billion, a P/E ratio of 47.10, a price-to-earnings-growth ratio of 3.62 and a beta of 1.
29. Insulet (NASDAQ:PODD – Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.
15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15.
The firm had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million.
Insulet had a net margin of 20.19% and a return on equity of 24.46%.
As a group, sell-side analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.
Analyst Upgrades and DowngradesSeveral research analysts recently commented on PODD shares. Wells Fargo & Company lifted their target price on shares of Insulet from $305.00 to $322.
00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. TD Cowen boosted their price objective on shares of Insulet from $264.00 to $324.
00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Piper Sandler increased their target price on shares of Insulet from $285.00 to $310.
00 and gave the stock an “overweight” rating in a report on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on Insulet from $280.
00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Finally, Canaccord Genuity Group increased their price objective on Insulet from $304.
00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock.
Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.Get Our Latest Analysis on InsuletInsiders Place Their BetsIn other news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st.
The stock was sold at an average price of $280.00, for a total value of $3,470,320.00.
Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position.
The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.47% of the company’s stock.
About Insulet (Free Report)Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.Recommended StoriesFive stocks we like better than InsuletWhat is a Bond Market Holiday? How to Invest and TradeInnovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of StartupsHow to Invest in Blue Chip StocksNVIDIA Insiders Sell: This Is What It Means for the Market How to Start Investing in Real EstateSpace Stocks Bottoming: Which Are Positioned Best for a Bounce?Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD – Free Report)..
